Your session is about to expire
← Back to Search
Immunotherapy + Targeted Therapy for Genitourinary Cancers
Study Summary
This trial is studying a combination of drugs as a possible treatment for rare genitourinary tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 2 trial • 13 Patients • NCT02315430Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a history of certain cancers or health conditions.I haven't had any major surgeries recently.My cancer's type and stage have been confirmed with a biopsy.I have had an organ or stem cell transplant.I do not have any severe illnesses that are not under control.My cancer has not spread to major blood vessels or the digestive system.You have not had a serious allergic reaction to any monoclonal antibody.I do not have any active cancer spread to my brain.I am 18 years old or older.I have had no more than 2 cancer treatments or none at all.I can swallow pills.I manage my condition with creams or hormone replacements.I have recovered from side effects of my previous treatments.I am not taking warfarin or certain long-term medications.I haven't had any major medical events or treatments recently.I have or had an autoimmune disease that could come back.I am mostly self-sufficient and active.I do not have an active autoimmune disease or a history of one that might come back.I have not recently had chemotherapy, radiation, or other specific cancer treatments.I do not have recent serious heart, stomach, or other specific health issues.My cancer has spread to new areas or worsened, as shown on scans.I haven't needed treatment for any cancer besides my current one in the last 2 years.You must not have a positive test for hepatitis B or hepatitis C.You have had a serious allergic reaction to any monoclonal antibody in the past.You have a positive test for hepatitis B or hepatitis C.Your blood and other body chemistry levels need to be within certain ranges.I have taken a pregnancy test within the last week and it was negative.
- Group 1: Treatment (cabozantinib, nivolumab, ipilimumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any North American medical centers that have initiated this research?
"Epic Care Partners in Cancer Care, located in Emeryville, California; Saint Francis Medical Center situated in Cape Girardeau, Missouri; and the Missouri Baptist Outpatient Centre-Sunset Hills based out of Sunset Hills, Michigan are among the 100 other trial sites currently recruiting patients."
Has the regulatory body given its blessing to Cabozantinib S-malate?
"Cabozantinib S-malate's safety is rated at 2 due to the Phase 2 trial, which has evidence of its security but no proof of efficacy."
What illnesses has Cabozantinib S-malate been found to be efficacious in alleviating?
"Cabozantinib S-malate is a common remedy for unresectable melanoma, but has also been used to treat squamous cell carcinoma, high recurrence risk cases, and other illnesses."
How many participants are taking part in the research trial?
"Affirmative, per the clinicaltrials.gov portal this medical study is currently recruiting individuals for participation. The trial was initially posted on April 12th 2019 and recently updated on November 24th 2022. This research requires 224 participants from 100 sites to be recruited."
Is the recruitment process for this trial still open?
"Yes, according to clinicaltrials.gov this research project is currently seeking participants. It was initially advertised on April 12th 2019 and the most recent edit happened on November 24th 2022. A total of 224 volunteers are needed from 100 different sites."
Are there any past experiments that utilized Cabozantinib S-malate?
"At present, there is a total of 841 clinical trials being conducted for Cabozantinib S-malate with 94 taking place in the third phase. Although Pittsburgh, Pennsylvania hosts many of these studies, 46024 sites are currently evaluating this medication."
Share this study with friends
Copy Link
Messenger